DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for seminoma — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSeminoma maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for seminoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
DNA topoisomerase II alpha (TOP2A) — TOP2A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 5s,5ar,8ar,9rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZY5 · 3.6 Å · ligand (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol
-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside (EVP). Experimental structure, not a prediction.
What the evidence adds up to
Seven patients with anaplastic variant seminoma were treated between 1986 and 2006 at one Israeli centre. Six had stage I disease, one had stage IIA. All received radiotherapy after orchiectomy, with doses from 2,500 to 3,000 cGy; the stage IIA patient got an additional 1,000 cGy boost. After a mean follow-up of 11 years, six patients were alive with no evidence of disease. One patient died from an unknown non-oncological cause while in complete remission. The authors note the low patient numbers and retrospective design, and state that the general consensus from large-scale studies now favours active surveillance for all stage I seminoma regardless of histologic variant.
A separate retrospective review of 320 stage I seminoma patients treated over 49 years (1960–2009) found that all but 12 received adjuvant radiotherapy. Median follow-up was 22.7 years. Acute gastrointestinal toxicity was grade 2 in 7.6% of patients. The 10-year disease-specific survival was 97.7% and relapse-free survival was 97.6%. Eight patients (2.7%) relapsed and were managed with chemotherapy. Six patients died of the disease, four died disease-free from other causes. The authors state that European consensus now makes surveillance the first choice, with radiotherapy or chemotherapy offered only if the patient declines surveillance.
For stage II seminoma with moderate-size retroperitoneal metastases (5–10 cm), a 1991 paper reports that primary infradiaphragmatic radiation leads to relapse in 20–35% of patients, though most of those relapses are then cured. The authors suggest that if chemotherapy with a better therapeutic ratio than current regimens becomes available, it might become the optimal first-line therapy for such patients.
A 2008 review of clinical stage I seminoma states that no treatment modality — radiotherapy, surveillance, or chemotherapy — has demonstrated a survival advantage over the others. The authors argue that the final decision depends on risk factors, patient preferences, and single-centre expertise. What remains missing is prospective data that directly compare these strategies in a randomised fashion with long-term toxicity endpoints, and a validated biomarker set that can stratify patients by relapse risk more precisely than current clinical features.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Rambam Maimonides Medical Journal · 2014 · 4 citations · open access
Anaplastic Variant of Classical Seminoma of the Testis: Northern Israel Oncology Center Experience and Brief Review of Literature
AbstractOBJECTIVES: There are only sporadic reports on the clinical behavior and appropriate treatment of anaplastic seminoma. This retrospective study summarizes our experience with the anaplastic variant of classical (typical) seminoma. METHODS: Between 1986 and 2006, seven anaplastic seminoma patients were staged and treated at the Northern Israel Oncology Center. Staging procedures included meticulous physical and neurological examinations, complete blood count, full biochemistry profile, specific tumor markers, testicular ultrasound, and other radiological measures. All patients underwent inguinal orchiectomy and were staged properly. Six patients had stage I disease, and one patient had stage IIA disease. Patients were irradiated with doses ranging from 2,500 to 3,000 cGy, and the stage IIA patient received an additional 1,000 cGy boost to radiographically involved lymph nodes. RESULTS: After a mean follow-up of 11 years, six patients are alive with no evidence of disease. One patient died due to an unknown, non-oncological, cause, unrelated to his previous testicular tumor, while in complete remission. CONCLUSIONS: Despite the low patient numbers and the retrospective nature of our study, it can be concluded that radiotherapy treatment for early-stage anaplastic seminoma patients might achieve the same excellent survival as for classical seminoma. However, the general consensus achieved through large-scale studies suggests that active surveillance should be offered to all stage I seminoma patients, regardless of the pathologic variant.
Management of Stage I Testicular Seminoma Over a Period of 49 Years
AbstractBACKGROUND: The aim of this study was to review the treatment, toxicity, and outcomes in patients with stage I seminoma after orchidectomy. PATIENTS AND METHODS: A retrospective chart review of all patients with stage I seminoma referred for initial treatment during the last 49 years was performed. Initial treatment approaches, toxicity, and outcomes were analyzed. RESULTS: A total of 320 patients were seen between 1960 and 2009. Median age at diagnosis was 37 years (range: 20-72), with a median follow-up of 22.7 years (range: 1-48). All patients but 12 were treated with adjuvant radiotherapy. Acute toxicity was mainly gastrointestinal, with 7.6% classified as grade 2. The 10-year disease-specific survival and relapse-free survival were 97.7 and 97.6%, respectively. 8 patients (2.7%) developed a relapse and were managed with chemotherapy. 10 patients died, 6 of the disease and 4 from other causes (disease-free at time of death). CONCLUSION: In the management of stage I seminoma, 3 treatment options are available; currently in the European Consensus, surveillance is the first choice, considering the overall comparable outcome and the low acute and late toxicity. Adjuvant radiotherapy and adjuvant chemotherapy should be considered as alternative options only if the patient declines the surveillance strategy.
The optimal treatment of patients with stage II seminoma with moderate size retroperitoneal metastases (5???10 cm)
AbstractSeminoma with moderate size retroperitoneal metastases is uncommon. When treated with primary infradiaphragmatic radiation, 20–35% will relapse, although the majority of these will be cured. When chemotherapy with a better therapeutic ratio than current regimens is defined for seminoma, it may become the optimal first-line therapy for such patients.
AbstractStage I seminoma is highly curable. There are different treatment options for this disease: radiotherapy, surveillance and chemotherapy. In recent years, adjuvant chemotherapy in particular has been extensively evaluated. This paper offers suggestions about the advantages and disadvantages of the different strategies, which will be discussed considering prognostic factors; future perspectives will also be evaluated. Through a review of the literature and their clinical experience, the authors outline the importance of prognostic factors in the management of patients suffering from seminomas. Although no treatment modalities have demonstrated survival advantages over others, acute and late side effects, acceptability and quality of life are the main elements of comparison between them. Our findings support the hypothesis that the final decision about the treatment of these tumors depends essentially on three different aspects: risk factors, the patient's own preferences, and single-center expertise. These aspects should play a fundamental role in the final decision-making.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
